Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease

Judith Wellens, Matthew Edmans, Uri Obolski, Colleen GC McGregor, Peter Simmonds, Marc Turner, Lisa Jarvis, Donal Skelley, Susanna Dunachie, Eleanor Barnes, David W Eyre, Jean-Frederic Colombel, Serre-Yu Wong, Paul Klenerman, James O Lindsey, Jack Satsangi, View ORCID ProfileCraig P Thompson
doi: https://doi.org/10.1101/2021.10.13.21264916
Judith Wellens
1Translational Gastro-intestinal Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford
2Translational Research for Gastrointestinal Diseases, University hospitals Leuven, Herestraat, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew Edmans
1Translational Gastro-intestinal Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford
3Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Uri Obolski
4School of Public Health, Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
5Porter School of Environmental and Earth Sciences, Faculty of Exact Sciences, Tel-Aviv University, TelAviv, Israel
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colleen GC McGregor
1Translational Gastro-intestinal Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Simmonds
3Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Turner
6National Microbiology Reference Unit, Scottish National Blood Transfusion Service, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lisa Jarvis
6National Microbiology Reference Unit, Scottish National Blood Transfusion Service, Edinburgh, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Donal Skelley
3Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susanna Dunachie
9Department of Microbiology/Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
10Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, UK
11Mahidol-Oxford Tropical Medicine Research Unit, Mahidol University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eleanor Barnes
1Translational Gastro-intestinal Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford
3Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W Eyre
9Department of Microbiology/Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK
12Nuffield Department of Population Health, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Frederic Colombel
14Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Serre-Yu Wong
14Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Klenerman
1Translational Gastro-intestinal Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford
3Nuffield Department of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James O Lindsey
15Centre for Immunobiology, Blizard Institute, Queen Mary University of London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jack Satsangi
1Translational Gastro-intestinal Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig P Thompson
16Department of Biology, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Craig P Thompson
  • For correspondence: craigpeterthompson@gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

There is substantial interest regarding the perceived risk that immunomodulator and biologic therapy could have on COVID-19 disease severity among patients with inflammatory bowel disease (IBD) and clinicians. In this study, we show that infliximab/thiopurine combination therapy is associated with significantly lower IgA, a range of lower IgG responses as well as impaired neutralising antibody responses, compared to responses observed in healthy individuals. We also demonstrate that whilst IgG responses were significantly reduced in individuals with IBD treated with infliximab or vedolizumab monotherapy compared to healthy controls, there was no significant reduction in IgA and neutralising antibody responses. As neutralising antibody responses correlate with protection, this observation may provide the mechanistic explanation for the observation reported by the SECURE-IBD study that individuals on infliximab/thiopurine combination therapy were at greater risk of severe COVID-19 outcomes than patients on monotherapy.

Competing Interest Statement

JS has received lecture fees from Takeda and from the Falk Foundation.

Funding Statement

ME was supported by the Helmsley Trust as part of the ICARUS-IBD study [Grant Number 2107 04731]. This healthcare worker study was funded by the UK Department of Health and Social Care as part of the PITCH (Protective Immunity from T cells to Covid-19 in Health workers) Consortium, with contributions from UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC), the Huo Family Foundation and The National Institute for Health Research (UKRIDHSC COVID-19 Rapid Response Rolling Call, Grant Reference Number COV19-RECPLAS). None of our funding bodies had any role in study design, data acquisition, data analysis or reporting of the results.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Samples from Oxford IBD patients were collected as a project (ref: ORB 20/A054) under the ethical approval of the Oxford Radcliffe Biobank, a research tissue bank that has a favourable opinion from the Oxford C South Central REC (ref:19/ SC/0173). Samples from London IBD patients were collected as a project under the ethical approval of the Digestive Disease Bioresource, Barts Health NHS Trust, a research tissue bank that has a favourable opinion from the Bromley REC, (ref: 15/LO/2127). Deidentified data from staff testing and patients were obtained from the Infections in Oxfordshire Research Database (IORD) which has generic Research Ethics Committee, Health Research Authority and Confidentiality Advisory Group approvals (19/SC/0403, ECC5-017(A)/2009). Healthy control participants were recruited under the GI Biobank Study 16/YH/0247, approved by the research ethics committee (REC) at Yorkshire & The Humber - Sheffield Research Ethics Committee on 29 July 2016, which has been amended for this purpose on 8 June 2020.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted October 18, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease
Judith Wellens, Matthew Edmans, Uri Obolski, Colleen GC McGregor, Peter Simmonds, Marc Turner, Lisa Jarvis, Donal Skelley, Susanna Dunachie, Eleanor Barnes, David W Eyre, Jean-Frederic Colombel, Serre-Yu Wong, Paul Klenerman, James O Lindsey, Jack Satsangi, Craig P Thompson
medRxiv 2021.10.13.21264916; doi: https://doi.org/10.1101/2021.10.13.21264916
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Combination therapy of infliximab and thiopurines, but not monotherapy with infliximab or vedolizumab, is associated with attenuated IgA and neutralisation responses to SARS-CoV-2 in inflammatory bowel disease
Judith Wellens, Matthew Edmans, Uri Obolski, Colleen GC McGregor, Peter Simmonds, Marc Turner, Lisa Jarvis, Donal Skelley, Susanna Dunachie, Eleanor Barnes, David W Eyre, Jean-Frederic Colombel, Serre-Yu Wong, Paul Klenerman, James O Lindsey, Jack Satsangi, Craig P Thompson
medRxiv 2021.10.13.21264916; doi: https://doi.org/10.1101/2021.10.13.21264916

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Gastroenterology
Subject Areas
All Articles
  • Addiction Medicine (271)
  • Allergy and Immunology (559)
  • Anesthesia (135)
  • Cardiovascular Medicine (1778)
  • Dentistry and Oral Medicine (240)
  • Dermatology (173)
  • Emergency Medicine (317)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (662)
  • Epidemiology (10834)
  • Forensic Medicine (8)
  • Gastroenterology (595)
  • Genetic and Genomic Medicine (2968)
  • Geriatric Medicine (289)
  • Health Economics (534)
  • Health Informatics (1938)
  • Health Policy (837)
  • Health Systems and Quality Improvement (747)
  • Hematology (295)
  • HIV/AIDS (634)
  • Infectious Diseases (except HIV/AIDS) (12535)
  • Intensive Care and Critical Care Medicine (697)
  • Medical Education (300)
  • Medical Ethics (89)
  • Nephrology (325)
  • Neurology (2819)
  • Nursing (152)
  • Nutrition (435)
  • Obstetrics and Gynecology (560)
  • Occupational and Environmental Health (600)
  • Oncology (1475)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (259)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (382)
  • Pediatrics (870)
  • Pharmacology and Therapeutics (368)
  • Primary Care Research (341)
  • Psychiatry and Clinical Psychology (2653)
  • Public and Global Health (5393)
  • Radiology and Imaging (1019)
  • Rehabilitation Medicine and Physical Therapy (599)
  • Respiratory Medicine (729)
  • Rheumatology (330)
  • Sexual and Reproductive Health (294)
  • Sports Medicine (280)
  • Surgery (329)
  • Toxicology (48)
  • Transplantation (151)
  • Urology (127)